New gout pill HEC93077 passes first safety check in humans
NCT ID NCT05127772
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called HEC93077 in 126 healthy volunteers and people with high uric acid (gout). The goal was to check safety, how the body processes the drug, and the effect of food. Participants took single or multiple doses for up to 14 days. Results will guide future studies on whether this drug can help control gout.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HEC93077 (an experimental oral drug to lower uric acid)
- What this could lead to
- If successful, this could lead to a new daily pill to control uric acid levels and prevent gout attacks.
- What could go wrong
- This is an early Phase 1 trial focused on safety and dosing, not on proving the drug works. Many drugs fail in later, larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Universicity Care of Luzhong Hospital
Zibo, Shandong, 255400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection tame Gout's uric acid?
- Can an ancient herbal formula tame gout?
- New drug combo aims to tame stubborn gout flares
- Timing matters: study tests if starting gout drug during a flare is safe
- Ultrasound may solve arthritis diagnosis puzzle
- Probiotic supplement shows promise for gout prevention in small study